We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Mutation That Induces High Blood Pressure in Women Linked to Increased Heart Attack Risk

By LabMedica International staff writers
Posted on 05 Aug 2014
A mutation in women in the G-protein coupled estrogen receptor 30 (GPER) gene generates a receptor with reduced activity that induces high blood pressure, the single biggest risk factor for heart attack and stroke.

The GPER gene is a member of the G-protein coupled receptor 1 family and encodes an integral membrane protein with high affinity for estrogen that localizes to the endoplasmic reticulum. The protein binds estrogen, resulting in intracellular calcium mobilization and synthesis of phosphatidylinositol 3,4,5-trisphosphate in the nucleus. This protein plays a role in the rapid nongenomic signaling events widely observed following stimulation of cells and tissues with estrogen.

Investigators at the Schulich School of Medicine & Dentistry (London, ON, Canada) found that a common missense genetic variant of GPER, P16L GPER, was poorly functional when expressed in vascular smooth muscle cells. Furthermore, females—but not males—carrying this genetic variant had increased blood pressure and had a higher allelic prevalence in a highly selected population of hard-to-treat hypertensive patients.

"This is one step in understanding the effects of estrogen on heart disease, and understanding why some women are more prone to heart attack and stroke than others," said senior author Dr. Ross Feldman, professor of medicine and physiology/pharmacology at the Schulich School of Medicine & Dentistry. "Our work is a step forward in developing approaches to treating heart disease in this under-appreciated group of patients."

The study was published in the July 21, 2014, online edition of the British Journal of Clinical Pharmacology.

Related Links:

Schulich School of Medicine & Dentistry


Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Clinical Chemistry System
P780
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay

Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Industry

view channel
Image: The LIAISON NES molecular point-of-care platform (Photo courtesy of Diasorin)

Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform

Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more